Mechano Growth Factor
Also referenced as: MGF, IGF-1Ec E-domain, MGF-24aa-E
An ambiguous research term covering IGF-1Ec splice biology and synthetic E-domain fragments.
- Evidence grade
- DPreclinical Research
Preclinical Research
- Regulatory status
- Research Use Only
Not FDA-approved for the research uses discussed; no established clinical enhancement indication.
- Human data
- No
No registered clinical trials identified
- Last reviewed
- October 27, 2026
Overview
An ambiguous research term covering IGF-1Ec splice biology and synthetic E-domain fragments.
Not FDA-approved for the research uses discussed; no established clinical enhancement indication.
A commercial MGF fragment, PEG-MGF and mature IGF-1 cannot be treated as interchangeable molecules.
Why It's Being Studied
- Muscle adaptation
- IGF splice-product biology
Mechanism of Action
The full splice-product biology and an isolated synthetic fragment are not the same as mature IGF-1 receptor signalling.
The full splice-product biology and an isolated synthetic fragment are not the same as mature IGF-1 receptor signalling. A commercial MGF fragment, PEG-MGF and mature IGF-1 cannot be treated as interchangeable molecules.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- Muscle adaptation
- IGF splice-product biology
- Cell and animal research
Evidence Summary
Cell and animal findings do not establish human muscle-repair efficacy for commercial MGF or PEG-MGF products.
Higher tiers carry more weight. Filled tiers have evidence for Mechano Growth Factor; tap to read it.
- Cell and animal findings do not establish human muscle-repair efficacy for commercial MGF or PEG-MGF products.
2 cited sources.
- In-vitro study2
Preclinical evidence
- Cell and animal findings do not establish human muscle-repair efficacy for commercial MGF or PEG-MGF products.
Reported Adverse Events in Research
- Identity, human pharmacology and long-term proliferative safety remain unresolved.
Limitations of Current Evidence
- A commercial MGF fragment, PEG-MGF and mature IGF-1 cannot be treated as interchangeable molecules.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| Mechano Growth Factor | Trofinetide | |
|---|---|---|
| Evidence grade | D — Preclinical Research | B — Moderate Human Evidence |
| Regulatory status | Research Use Only | FDA Approved for Specific Indication |
| Human data | No | Yes |
| Clinical trials | None identified | Registered trials exist |
| Research routes | Cell and animal research | Oral approved medicine |
| Cited sources | 2 | 2 |
Frequently Asked Questions
Research References
- In-vitro study
Mechano Growth Factor — in-vitro study
- In-vitro study
E-domain fragment research